TheraVet Announces the Launch of the Pivotal European Multicentric Clinical Study of VISCO-VET in Canine Osteoarthritis
10 Septembre 2021 - 7:30AM
Business Wire
- Pivotal clinical trial of VISCO-VET in canine osteoarthritis
approved in France and Netherlands
- First investigating site initiated in France
- Start of patients enrolment anticipated in October
2021
Regulatory News:
TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 -
ticker: ALVET), a pioneering company in the management of
osteoarticular diseases in pets, today announces the launch of
the pivotal European multicentric clinical study assessing
VISCO-VET in canine osteoarthritis.
VISCO-VET, TheraVet’s viscoregenerative gel, will be assessed in
a prospective, multicentric, controlled, double-blinded,
randomized, pivotal field study in client-owned dogs suffering from
osteoarthritis (OA). The study will evaluate the potential of a
unique intra-articular injection of VISCO-VET in stifle or elblow
to improve dog’s mobility and reduce pain compared to a non-treated
control group. Patients will be followed for 3 months.
In the study, 154 client-owned dogs with osteoarthritis will be
enrolled. The study will be conducted in 20 centers in four (4)
countries including France, Netherlands, Portugal and Poland. The
Company has received the approval in France and Netherlands and has
just started the initiation of the investigating sites in these
countries. The approval in the remaining territories is expected to
be obtained in the following weeks. First patient treated is
expected in October 2021.
An update on patients recruitment will be provided in the second
quarter of 2022, following by top-line interim analyses
results.
Enrico Bastianelli, Chief Executive Officer of TheraVet,
concludes: “Following the positive efficacy and safety results
of VISCO-VET in the proof-of-concept study, we are very delighted
to initiate the patient recruitment of this pivotal trial for
VISCO-VET.”
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for animals. The Company develops
targeted, safe and effective treatments to improve the quality of
life of pets suffering from osteoarticular diseases. For pet
owners, the health of their pets is a major concern and TheraVet’s
mission is to address the need for innovative and curative
treatments. TheraVet works closely with international opinion
leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Jumet, Belgium, and it has a subsidiary in the US.
For more information, visit the TheraVet website
Or follow us on LinkedIn / Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210909005822/en/
TheraVet Sabrina Ena Chief Operating Officer
Sabrina.ena@thera.vet Tel: +32 (0) 71 18 32 49
Julie Winand Chief Corporate Officer julie.winand@thera.vet Tel: +32 (0) 71 18 32
49
NewCap Investor Relations and Financial Communications
Louis Tilquin / Olivier Bricaud theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
